Morgan Stanley maintains Denali Therapeutics at Overweight, raises price target to $42 from $40
Morgan Stanley kept its Overweight rating on Denali Therapeutics and increased its price target to $42 from $40, suggesting a 115.9% upside from the Nov 3 close of $19.45, according to the firm.
How this was made
The 30-second read
Why it matters
Analyst upgrade may attract short-term buying and raise the stock's valuation.
Market read
The new target provides a fresh catalyst for traders to consider positioning in DNL.
What to watch
Potential regulatory or trial setbacks not reflected in the target.
Background
Denali Therapeutics is a clinical-stage biotech focused on neurodegenerative diseases.
Market effects
May lift sentiment in the biotech sector as peers could see similar upgrades.
Limited to US-listed biotech investors.
Low, confined to Denali and its immediate peers.
Counterpoint
The target raise could be premature if upcoming trial data disappoints.
Key entities
- AnalystMorgan Stanley
Equity research firm that issued the price target raise.
